Secukinumab 化学特性,用途語,生産方法
作用機序
Secukinumab is unique from other approved therapies for psoriasis as it is a first-in-class recombinant high-affinity, fully human monoclonal antibody of the IgG1/kappa isotype that selectively targets IL-17A. Secukinumab interferes in the psoriasis pathologic process by selectively binding to IL-17A, thereby preventing IL-17A interaction with the IL-17 receptor expressed on, for example, keratinocytes[1].
Secukinumab 上流と下流の製品情報
原材料
準備製品